Cotargeting a MYC/eIF4A-survival axis improves the efficacy of KRAS inhibitors in lung cancer
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index; 4 of the 14 sources its claims cite were checked for support.
Abstract
Despite the success of KRAS G12C inhibitors in non-small cell lung cancer (NSCLC), more effective treatments are needed. One preclinical strategy has been to cotarget RAS and mTOR pathways; however, toxicity due to broad mTOR inhibition has limited its utility. Therefore, we sought to develop a more refined means of targeting cap-dependent translation and identifying the most therapeutically important eukaryotic initiation factor 4F complex-translated (eIF4F-translated) targets. Here, we show that an eIF4A inhibitor, which targets a component of eIF4F, dramatically enhances the effects of KRAS G12C inhibitors in NSCLCs and together these agents induce potent tumor regression in vivo. By screening a broad panel of eIF4F targets, we show that this cooperativity is driven by effects on BCL-2 family proteins. Moreover, because multiple BCL-2 family members are concomitantly suppressed, these agents are broadly efficacious in NSCLCs, irrespective of their dependency on MCL1, BCL-xL, or BCL-2, which is known to be heterogeneous. Finally, we show that MYC overexpression confers sensitivity to this combination because it creates a dependency on eIF4A for BCL-2 family protein expression. Together, these studies identify a promising therapeutic strategy for KRAS-mutant NSCLCs, demonstrate that BCL-2 proteins are the key mediators of the therapeutic response in this tumor type, and uncover a predictive biomarker of sensitivity.
Overview
CoChat Summary
TL;DR
eIF4A inhibition with eFT226 potently sensitizes KRAS-mutant NSCLCs to KRAS G12C or MEK inhibitors, causing apoptosis and durable tumor regression in preclinical models. The effect is driven by suppression of multiple BCL-2 family prosurvival proteins, and MYC amplification/overexpression marks sensitivity.
Key findings
- eFT226 plus MRTX849 sensitized 75% of KRAS G12C–mutant NSCLC cell lines, with loss of approximately 60%–90% of cells within 3 days; eFT226 plus trametinib was cytotoxic in 9 of 13 KRAS-mutant lines.
- In vivo, MRTX849 plus eFT226 caused 50%–75% tumor regression over 28 days in H23 xenografts and up to 85%–90% regression in the KRAS G12C–mutant PDX DFCI-730; eFT226 also promoted sustained regression with trametinib in KRAS G12A and G12V models.
- The combination cooperatively triggered apoptosis in approximately 50% of sensitive cells after 48–72 hours and suppressed MCL1, BCL-xL, and/or BCL-2; resistant cells did not substantially suppress these prosurvival proteins.
- MYC amplifications were present in 7 of 9 sensitive cell lines and 0 of 4 resistant lines; ectopic MYC expression converted all 4 resistant lines to sensitive, and high-MYC patient-derived organotypic spheroids were sensitive whereas low-MYC were resistant.
Methods
- Human KRAS-mutant NSCLC cell lines were tested in 3D spheroid and modified 2D assays, short- and long-term proliferation assays, siRNA knockdowns, lentiviral overexpression, Western blotting, immunoprecipitation, and Incucyte live-cell caspase-3/7 apoptosis imaging.
- Synergy was assessed with SynergyFinder using the highest single agent (HSA) model; drug treatments included eFT226, MRTX849, trametinib, navitoclax, venetoclax, S63845, and palbociclib.
- In vivo studies used H23, H1573, H441, and H2030 xenografts and DFCI-730 PDX models; ex vivo studies used patient-derived organotypic tumor spheroids (PDOTSs) from 5 KRAS G12C–mutant lung adenocarcinoma samples, plus CCLE/cBioPortal MYC copy-number analysis and GSEA.
Limitations
- The paper does not include a formal limitations section.
- Evident from the text: the therapeutic strategy is preclinical, relying on cell lines, xenografts, PDX, and PDOTS models rather than clinical trial data.
- The authors note that the triple combination of eIF4A, BCL-xL/BCL-2, and KRAS G12C inhibitors exerted the strongest cytotoxic effects but “would not likely be tolerated,” and they position eIF4Ai+KRASi as the alternative promising combination.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures









Verification
Claims the paper makes
4 Valid · 0 Not valid · 2 Not checked · 41 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“This finding is particularly important for NSCLCs, as this tumor type has been shown to exhibit a heterogeneous dependency on MCL1, BCL-xL, and BCL-2 (28).”
§ Cotargeting a MYC/eIF4A-survival axis improves the efficacy of KRAS inhibitors in lung cancer > Discussion
What the sources say
- Partly supportedcites [28] Nangia V et al Exploiting MCL1 dependency with combination MEK + MCL1 inhibitors leads to induction of apoptosis and tumor regression in KRAS-mutant non-small cell lung cancer Cancer Discov 2018 8 12 1598 1613 10.1158/2159-8290.CD-18-0277 30254092 PMC6279543 sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) says apoptotic dependencies vary among KRAS-mutant NSCLC cell lines, which may depend on MCL-1, BCL-XL, both, or neither. The Results (page unavailable) report very little activity from the selective BCL-2 inhibitor venetoclax, so the paper does not support including BCL-2 as a demonstrated dependency; its findings are also specific to KRAS-mutant cell lines rather than all NSCLC. (LLM, conf=0.90)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“This observation is consistent with reports that the RAS/MEK/ERK pathway also regulates many of these same genes via transcriptional and posttranslational mechanisms (27, 35–37).”
§ Cotargeting a MYC/eIF4A-survival axis improves the efficacy of KRAS inhibitors in lung cancer > Discussion
What the sources say
- Not checked — no full text of the sourcecites [27] Balmanno K Cook SJ Tumour cell survival signalling by the ERK1/2 pathway Cell Death Differ 2009 16 3 368 377 10.1038/cdd.2008.148 18846109 source
- Not checked — no full text of the sourcecites [35] Boucher MJ et al MEK/ERK signaling pathway regulates the expression of Bcl-2, Bcl-X(L), and Mcl-1 and promotes survival of human pancreatic cancer cells J Cell Biochem 2000 79 3 355 369 10.1002/1097-4644(20001201)79:3<355::AID-JCB20>3.0.CO;2-0 10972974 doi:10.1002/1097-4644(20001201)79:3
- Partly supportedcites [36] Ewings KE et al ERK1/2-dependent phosphorylation of BimEL promotes its rapid dissociation from Mcl-1 and Bcl-xL EMBO J 2007 26 12 2856 2867 10.1038/sj.emboj.7601723 17525735 PMC1894764 sourceExperimental — accuracy not yet measured
The Introduction (page not available) reports that Bim mRNA increases when ERK1/2 signaling is inactivated, and the Results section on ERK1/2 activation reports posttranslational phosphorylation and dissociation of BimEL from Mcl-1 and Bcl-xL. This supports regulation of Bim through both mechanisms, but this paper does not establish that the pathway regulates many BCL-2 family genes. (LLM, conf=0.85)
- Not checked yetcites [37] Zaanan A et al The mutant KRAS gene up-regulates BCL-XL protein via STAT3 to confer apoptosis resistance that is reversed by BIM protein induction and BCL-XL antagonism J Biol Chem 2015 290 39 23838 23849 10.1074/jbc.M115.657833 26245900 PMC4583008 source
Checked before — its earlier verdict is held back until a new check runs.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“MYC amplifications were present in 7 of 9 sensitive cell lines and in 0 of 4 resistant cell lines”
§ Cotargeting a MYC/eIF4A-survival axis improves the efficacy of KRAS inhibitors in lung cancer > Results > MYC is amplified and/or overexpressed in tumor cells that are sensitive to eIF4A and RAS pathway inhibitors.
plainstates an associationn = 9- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In this study, we show that eIF4A inhibitors dramatically sensitize NSCLCs to KRAS G12C inhibitors.”
§ Cotargeting a MYC/eIF4A-survival axis improves the efficacy of KRAS inhibitors in lung cancer > Discussion
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“the suppression of BCL-2 family genes potently cooperated with MRTX849 or trametinib to kill cells”
§ Cotargeting a MYC/eIF4A-survival axis improves the efficacy of KRAS inhibitors in lung cancer > Results > Suppression of multiple prosurvival proteins, but not other oncogenic targets, underlies the therapeutic response to combined eIF4A and KRAS G12C inhibitors.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 47 claims and to verify the 1 reference still open.
- Probably not a substantial claim. 11
- It may state two separate claims as one. 8
Citations
Cites
Next-generation characterization of the Cancer Cell Line Encyclopedia
Ghandi, M., Huang, F. W., Jané-Valbuena, J., Kryukov, G. V., Lo, C. C., McDonald, E. R., Barretina, J., Gelfand, E. T., Bielski, C. M., Li, H., et al. (2019) · Nature · doi:10.1038/s41586-019-1186-3 · Cited by 3,394 · cited 1×
“MYC allelic copy number was characterized as deletion, diploid, or amplification (39).”
Self-citationHallin, J., Engstrom, L. D., Hargis, L., Calinisan, A., Aranda, R., Briere, D. M., Sudhakar, N., Bowcut, V., Baer, B. R., Ballard, J. A., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1167 · Cited by 1,304 · cited 3×
“Because KRAS G12C inhibitors have been shown to be more effective in 3D cell-growth assays, the effects of these agents were first assessed under conditions that promote spheroid formation, as previously described (3, 20) (Figure 1A).”
Targeting KRAS mutant cancers with a covalent G12C-specific inhibitor
Janes, M. R., Zhang, J., Li, L.-S., Hansen, R., Peters, U., Guo, X., Chen, Y., Babbar, A., Firdaus, S. J., Darjania, L., et al. (2018) · Cell · doi:10.1016/j.cell.2018.01.006 · Cited by 1,172 · cited 1×
“Because KRAS G12C inhibitors have been shown to be more effective in 3D cell-growth assays, the effects of these agents were first assessed under conditions that promote spheroid formation, as previously described (3, 20) (Figure 1A).”
MYC as a regulator of ribosome biogenesis and protein synthesis
van Riggelen, J., Yetil, A., & Felsher, D. W. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2819 · Cited by 956
Targeting the translation machinery in cancer
Bhat, M., Robichaud, N., Hulea, L., Sonenberg, N., Pelletier, J., & Topisirovic, I. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4505 · Cited by 799 · cited 1×
“Many direct eIF4A/eIF4F mRNA targets have been identified and often encode proteins that drive proliferation, metastasis, and survival (11, 14, 15).”
Discovery of a Covalent Inhibitor of KRAS G12C (AMG 510) for the Treatment of Solid Tumors
Lanman, B. A., Allen, J. R., Allen, J. G., Amegadzie, A. K., Ashton, K. S., Booker, S. K., Chen, J. J., Chen, N., Frohn, M. J., Goodman, G., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01180 · Cited by 765 · cited 1×
“Fortunately, covalent inhibitors of KRAS G12C, the most frequent KRAS mutation in NSCLCs (~40%), have been developed and are showing promise in the clinic (2, 3).”
Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids
Jenkins, R. W., Aref, A. R., Lizotte, P. H., Ivanova, E., Stinson, S., Zhou, C. W., Bowden, M., Deng, J., Liu, H., Miao, D., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0833 · Cited by 594 · cited 3×
“In addition, to investigate whether high MYC levels might be useful for prospectively predicting sensitivity to combined KRAS G12C/eIF4A inhibitors, human KRAS G12C–mutant NSCLC explants expressing either high levels of MYC (DFCI-730, DFCI-456, MGH-9029-1B) or low levels of MYC (MGH-1112-1, MGH-1196-2) were used to ge…”
InfluentialSelf-citationVertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition
Ryan, M. B., Fece de la Cruz, F., Phat, S., Myers, D. T., Wong, E., Shahzade, H. A., Hong, C. B., & Corcoran, R. B. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3523 · Cited by 496
Tumour cell survival signalling by the ERK1/2 pathway
Balmanno, K., & Cook, S. J. (2009) · Cell Death & Differentiation · doi:10.1038/cdd.2008.148 · Cited by 484 · cited 2×
“Importantly, the RAS/ERK pathway is known to converge on several of these same targets and can also control their expression by affecting transcription (e.g., cyclin D1) or protein stability (e.g., MCL1) (26, 27).”
Targeting the eIF4F Translation Initiation Complex: A Critical Nexus for Cancer Development
Pelletier, J., Graff, J., Ruggero, D., & Sonenberg, N. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2789 · Cited by 367 · cited 2×
“However, the translational control of these targets by eIF4A appears to be very tumor-type specific (11, 15).”
Blumenschein, G. R., Smit, E. F., Planchard, D., Kim, D.-W., Cadranel, J., De Pas, T., Dunphy, F., Udud, K., Ahn, M.-J., Hanna, N. H., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv072 · Cited by 349 · cited 1×
“Trametinib alone had little effect in these models, consistent with observed inefficacy of MEK inhibitors in NSCLC clinical trials (21, 22).”
Transcriptional regulation of the cyclin D1 gene at a glance
Klein, E. A., & Assoian, R. K. (2008) · Journal of Cell Science · doi:10.1242/jcs.039131 · Cited by 341 · cited 1×
“Importantly, the RAS/ERK pathway is known to converge on several of these same targets and can also control their expression by affecting transcription (e.g., cyclin D1) or protein stability (e.g., MCL1) (26, 27).”
Jänne, P. A., van den Heuvel, M. M., Barlesi, F., Cobo, M., Mazieres, J., Crinò, L., Orlov, S., Blackhall, F., Wolf, J., Garrido, P., et al. (2017) · JAMA · doi:10.1001/jama.2017.3438 · Cited by 335 · cited 1×
“Trametinib alone had little effect in these models, consistent with observed inefficacy of MEK inhibitors in NSCLC clinical trials (21, 22).”
Crystal structure of human KRAS G12C covalently bound to a phthalazine inhibitor: 6pgo
Mohr, C. (2019) · Worldwide Protein Data Bank · doi:10.2210/pdb6pgo/pdb · Cited by 314
KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target
Román, M., Baraibar, I., López, I., Nadal, E., Rolfo, C., Vicent, S., & Gil-Bazo, I. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0789-x · Cited by 301 · cited 1×
“1 Introduction While activating mutations in the KRAS oncogene occur in nearly one-third of non–small cell lung cancers (NSCLCs), effective therapeutic options for these malignancies remain limited (1).”
Translation control of the immune checkpoint in cancer and its therapeutic targeting
Xu, Y., Poggio, M., Jin, H. Y., Shi, Z., Forester, C. M., Wang, Y., Stumpf, C. R., Xue, L., Devericks, E., So, L., et al. (2019) · Nature Medicine · doi:10.1038/s41591-018-0321-2 · Cited by 261 · cited 1×
“While activating mutations in the KRAS oncogene occur in nearly one-third of non–small cell lung cancers (NSCLCs), effective therapeutic options for these malignancies remain limited (1).”
Rubio, C. A., Weisburd, B., Holderfield, M., Arias, C., Fang, E., DeRisi, J. L., & Fanidi, A. (2014) · Genome Biology · doi:10.1186/s13059-014-0476-1 · Cited by 200 · cited 1×
“E, CDK4), survival (e.g., MCL1, BCL-xL, BCL-2), transcription (e.g., YAP), metastasis (e.g., MMPs), angiogenesis (e.g., VEGF), immune recognition (e.g., PD-L1), and cell signaling (e.g., RAS, ERK, AKT, PI3K, MET, HER2) (14–16 , 23– 25).”
The Role of Myc-Induced Protein Synthesis in Cancer
Ruggero, D. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1970 · Cited by 186 · cited 2×
“NPM1, DKC1, NOP56, RRP1) based on previously published data (29).”
c-Myc and eIF4F Are Components of a Feedforward Loop that Links Transcription and Translation
Lin, C.-J., Cencic, R., Mills, J. R., Robert, F., & Pelletier, J. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5876 · Cited by 180
ERK1/2‐dependent phosphorylation of BimEL promotes its rapid dissociation from Mcl‐1 and Bcl‐xL
Ewings, K. E., Hadfield‐Moorhouse, K., Wiggins, C. M., Wickenden, J. A., Balmanno, K., Gilley, R., Degenhardt, K., White, E., & Cook, S. J. (2007) · The EMBO Journal · doi:10.1038/sj.emboj.7601723 · Cited by 176
The role of c-myc in regulation of translation initiation
Schmidt, E. V. (2004) · Oncogene · doi:10.1038/sj.onc.1207548 · Cited by 166
Ernst, J. T., Thompson, P. A., Nilewski, C., Sprengeler, P. A., Sperry, S., Packard, G., Michels, T., Xiang, A., Tran, C., Wegerski, C. J., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00182 · Cited by 150 · cited 1×
“Fortunately, a potent and selective small-molecule inhibitor of eIF4A, eFT226, has recently been developed and is currently being evaluated in clinical trials (18).”
The RasGAP Gene, RASAL2, Is a Tumor and Metastasis Suppressor
McLaughlin, S. K., Olsen, S. N., Dake, B., De Raedt, T., Lim, E., Bronson, R. T., Beroukhim, R., Polyak, K., Brown, M., Kuperwasser, C., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.08.004 · Cited by 135 · cited 1×
“pared, and virus was harvested as previously described (38).”
Self-citationMechanisms of Resistance to KRASG12C Inhibitors
Dunnett-Kane, V., Nicola, P., Blackhall, F., & Lindsay, C. (2021) · Cancers · doi:10.3390/cancers13010151 · Cited by 117
Molecular Pathways: The eIF4F Translation Initiation Complex—New Opportunities for Cancer Treatment
Malka-Mahieu, H., Newman, M., Désaubry, L., Robert, C., & Vagner, S. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2362 · Cited by 105 · cited 4×
“Because many oncogenic transcripts contain long and highly structured 5′ UTRs, they require eIF4A activity for their translation, suggesting that cancer cells may be more dependent on the activity of this helicase than normal cells (13).”
InfluentialTranslation Regulation as a Therapeutic Target in Cancer
Grzmil, M., & Hemmings, B. A. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0026 · Cited by 103 · cited 1×
“…translation, in particular, is commonly hyperactivated in tumors through genetic alterations in components of the eukaryotic initiation factor 4F complex (eIF4F) or due to aberrant activation of oncogenic pathways, including RAS/ERK, PI3K/mTOR, and MYC, which all converge on this complex (10–12).”
Nangia, V., Siddiqui, F. M., Caenepeel, S., Timonina, D., Bilton, S. J., Phan, N., Gomez-Caraballo, M., Archibald, H. L., Li, C., Fraser, C., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0277 · Cited by 94
Self-citationRiely, G. J., Ou, S.-H. I., Rybkin, I., Spira, A., Papadopoulos, K., Sabari, J. K., Johnson, M., Heist, R. S., Bazhenova, L., Barve, M., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/s1556-0864(21)01941-9 · Cited by 77 · cited 1×
“However, fewer than half of patients respond to these agents and responses are temporary (4, 5).”
The Role of Translation Control in Tumorigenesis and Its Therapeutic Implications
Xu, Y., & Ruggero, D. (2020) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030419-033420 · Cited by 67 · cited 3×
“A key component of the eIF4F complex is the RNA helicase eIF4A, which is required to unwind the secondary structures of cap-dependent transcripts (10, 17).”
Translational dysregulation in cancer: eIF4A isoforms and sequence determinants of eIF4A dependence
Raza, F., Waldron, J. A., & Quesne, J. L. (2015) · Biochemical Society Transactions · doi:10.1042/bst20150163 · Cited by 61 · cited 2×
“A key component of the eIF4F complex is the RNA helicase eIF4A, which is required to unwind the secondary structures of cap-dependent transcripts (10, 17).”
Zaanan, A., Okamoto, K., Kawakami, H., Khazaie, K., Huang, S., & Sinicrope, F. A. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.657833 · Cited by 59 · cited 1×
“Therefore, we believe that the shift in translational dependency is due to the combined effects on many of these components and not one specific target. tional and posttranslational mechanisms (27, 35–37).”
Thompson, P. A., Eam, B., Young, N. P., Fish, S., Chen, J., Barrera, M., Howard, H., Sung, E., Parra, A., Staunton, J., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-0973 · Cited by 50
Targeting Translation of mRNA as a Therapeutic Strategy in Cancer
Pal, I., Safari, M., Jovanovic, M., Bates, S. E., & Deng, C. (2019) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-019-00530-y · Cited by 46 · cited 2×
“However, the translational control of these targets by eIF4A appears to be very tumor-type specific (11, 15).”
Targeting eIF4A-Dependent Translation of KRAS Signaling Molecules
Singh, K., Lin, J., Lecomte, N., Mohan, P., Gokce, A., Sanghvi, V. R., Jiang, M., Grbovic-Huezo, O., Burčul, A., Stark, S. G., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-2929 · Cited by 39 · cited 1×
“E, CDK4), survival (e.g., MCL1, BCL-xL, BCL-2), transcription (e.g., YAP), metastasis (e.g., MMPs), angiogenesis (e.g., VEGF), immune recognition (e.g., PD-L1), and cell signaling (e.g., RAS, ERK, AKT, PI3K, MET, HER2) (14–16 , 23– 25).”
Overcoming adaptive resistance to KRAS inhibitors through vertical pathway targeting
Yaeger, R., & Solit, D. B. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-4060 · Cited by 39
Li, B., Skoulidis, F., Falchook, G., Sacher, A., Velcheti, V., Dy, G., Price, T., Borghaei, H., Schuler, M., Kato, T., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.01.321 · Cited by 30
Meric-Bernstam, F., Sharma, M., Sommerhalder, D., Skeel, R. T., El-Khoueiry, A. B., Caswell-Jin, J. L., Patel, P. H., & Rosen, E. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.2022.40.16_suppl.3081 · Cited by 17 · cited 1×
“Interim results show favorable tolerability, even when combined with other agents, and signs of clinical activity (19).”
Can the Help Match the Hype? KRASG12C-Specific Inhibitors and Beyond
Klempner, S. J., & Hata, A. N. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1255 · Cited by 15 · cited 1×
“In addition, KRAS G12C inhibitors are not relevant for the remaining approximately 60% of KRAS-mutant NSCLCs that harbor other mutant KRAS alleles (3, 6).”
Self-citationBoucher, M.-J., Morisset, J., Vachon, P. H., Reed, J. C., Lain�, J., & Rivard, N. (2000) · Journal of Cellular Biochemistry · doi:10.1002/1097-4644(20001201)79:3<355::aid-jcb20>3.0.co;2-0 · cited 1×
“Therefore, we believe that the shift in translational dependency is due to the combined effects on many of these components and not one specific target. tional and posttranslational mechanisms (27, 35–37).”
Cited by
Exploiting the therapeutic implications of KRAS inhibition on tumor immunity
Molina-Arcas, M., & Downward, J. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.02.012 · Cited by 152
Combinatorial strategies to target RAS-driven cancers
Perurena, N., Situ, L., & Cichowski, K. M. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-024-00679-6 · Cited by 114
Self-citationMYC and KRAS cooperation: from historical challenges to therapeutic opportunities in cancer
Casacuberta‐Serra, S., González-Larreategui, Í., Capitán-Leo, D., & Soucek, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01907-z · Cited by 99
Artificial Intelligence Application for Anti-tumor Drug Synergy Prediction
Peng, Z., Ding, Y., Zhang, P., Lv, X., Li, Z., Zhou, X., & Huang, S. (2024) · Current Medicinal Chemistry · doi:10.2174/0109298673290777240301071513 · Cited by 17
Self-citationThe Role of MYC in Tumor Immune Microenvironment Regulation: Insights and Future Directions
Nirala, B. K., & Yustein, J. T. (2025) · Frontiers in Bioscience-Landmark · doi:10.31083/fbl37304 · Cited by 20
“Additionally, an eIF4A inhibitor enhances the efficacy of KRAS G12C inhibitors in NSCLC by suppressing B-cell lymphoma (BCL)-2 family proteins, with MYC overexpression increasing sensitivity to this combination, highlighting a promising therapeutic strategy for KRAS-mutant NSCLC [55].”
Metadata
- Authors
- Nardi, F., Perurena, N., Schade, A. E., Li, Z.-H., Ngo, K., Ivanova, E. V., Saldanha, A., Li, C., Gokhale, P. C., Hata, A. N., Barbie, D. A., Paweletz, C. P., Jänne, P. A., & Cichowski, K.
- Affiliations
- Brigham and Women's Hospital (US)
- Dana-Farber Cancer Institute (US)
- Harvard University (US)
- Corresponding author
- Cichowski, Karen
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2023-08-15
- Volume
- 133
- Issue
- 16
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- PMC
- PMC10425214
- OpenAlex
- W4382630978
- Cited by
- 21
- References
- 39
- Citations by year
- 2026: 2 · 2025: 11 · 2024: 6 · 2023: 2
- FWCI
- 3.85
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of Clinical Investigation (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- NIH Clinical Center (R01CA111754, R35CA220497)
- The Ludwig Center at Harvard Medical School (112762)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Keywords
- KRAS G12C inhibitors, non-small cell lung cancer, eIF4F, c-Myc, Bcl-2 family proteins, cap-dependent translation, combination therapy, predictive biomarkers, Mcl-1, Bcl-xL, Bcl-2, tumor survival
- MeSH terms
- Carcinoma, Non-Small-Cell Lung, Humans, Lung Neoplasms, Mutation, Proto-Oncogene Proteins p21(ras), Proto-Oncogene Proteins c-bcl-2, Eukaryotic Initiation Factor-4F, Cell Line, Tumor, Protein Kinase Inhibitors, TOR Serine-Threonine Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.